College of Pharmacy

Avedisian Hall, 7 Greenhouse Road Kingston, RI 02881

pharmcol@etal.uri.eduOffice: 401.874.2761 Fax: 401.874.2181

URI
Think Big, We Do.
Rhode Island Seal

Continuing Professional Development

Office of Continuing Professional Development

Home Study Program
Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists

Activity Overview

Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists is an online educational program for prescribers, pharmacists, and other healthcare providers that will help you prevent overdoses among your patients and their social networks. Through the program you will see videos of patient-pharmacist-prescriber encounters that model how to provide a patient overdose education and a naloxone rescue kit. The program also includes very brief instructional videos for the available naloxone rescue kit formulations designed for you to use with your patients.

The online program located at http://www.opioidprescribing.com/naloxone_module_1-landing includes resources to help health care providers educate their patients to reduce overdose risk and provide naloxone rescue kits to patients and their social networks. Upon completion of the online program at http://www.opioidprescribing.com/naloxone_module_1-landing, pharmacists who wish to obtain CE credit should take the post-test below.

Presentation

Presentation Materials

Take Post-Test

Activity Information

Target Audience

Pharmacists, physicians, nurse practitioners, physician assistants, and nurses. All professions will find value in this training; however, completing the post-test on this site, only offers CE credit for pharmacists.

Learning Objectives

  1. Explain the epidemiology of overdose;
  2. Explain the rational for and scope of overdose prevention education and naloxone rescue kit distribution;
  3. Incorporate overdose prevention education and naloxone rescue kits into medical and pharmacy practice by a) educating patients about overdose risk reduction and b) furnishing naloxone rescue kits; and
  4. Explain the legal and policy environment regarding furnishing naloxone rescue kits.

Activity Faculty

Faculty Disclosure Statement

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Faculty and Disclosure Information

Daniel P. Alford, MD, MPH, FACP (Course Co-Director)
Associate Professor of Medicine
Boston University School of Medicine
Boston Medical Center
dan.alford@bmc.org

Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does not plan to discuss unlabeled/investigational uses of a commercial product.

Alexander Y. Walley, MD, MSc (Course Co-Director)
Assistant Professor of Medicine
Co-Program Director, Addiction Medicine Fellowship Program Program
Director, Fellow Immersion Training Program
Boston University School of Medicine and Boston Medical Center

Faculty member is a consultant for Social Sciences Innovation Research, Inc. Faculty member indicates that he does plan to discuss unlabeled/investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA. 

Jeffrey Bratberg, PharmD, BCPS
Clinical Professor of Pharmacy
University of Rhode Island College of Pharmacy
Infectious Disease Specialist
Roger Williams Medical Center, Providence, RI

Faculty member is a consultant for and on the speakers bureau for Merck, and on the speakers bureau for Sanofi Pasteur. Faculty member indicates that he does plan to discuss unlabeled/ investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Corey Davis, JD, MSPH
Deputy Director
The Network for Public Health Law

Faculty member has nothing to disclose with regards to commercial support. Faculty member indicates that he does plan to discuss unlabeled/investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Ilana Hardesty, Program Operations Manager, and Patti-Ann Collins, Lead Nurse Planner, Boston University School of Medicine CME Office, have nothing to disclose with regards to commercial support.

Traci Green, MD, and Nkiruka Emeagwali, MD, Video Actors, have nothing to disclose with regards to commercial support.  They do discuss unlabeled/investigational uses of a commercial product.  The intra-nasal delivery of naloxone is not approved by the FDA.

Hardware & Software Requirements

Activity Support

This program is provided by Boston University School of Medicine and is supported by an unrestricted educational grant from the Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services.

Accreditation Information

Accreditation Statement: The University of Rhode Island, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation: This program will provide the participant with 1.25 Contact Hours (0.1 25 CEUs) of continuing pharmacy education credit for completion of the home study and post-test. Participants will be able to print their statement of credit via the CPE Monitor after completing the post-test  following the activity.

Universal Activity Number (UAN): 0060-9999-14-062-H01-P.

Release Date: 10/15/2014

Expiration Date: 10/15/2017

Activity Type: This program is a knowledge-based continuing education activity.

Copyright © 2017 University of Rhode Island.

The University of Rhode Island
Think Big, We Do.
A-ZDirectoryContact UsJump to top